Sanofi Nears Deal to Buy Bioverativ for More Than $11.5 Billion

The French drugmaker finally looks set to clinch a big deal as it braces for generic competition for its top-selling product, after missing out on a number of opportunities.

from WSJ.com: US Business http://ift.tt/2n3piQn
via IFTTT